GLSI Stock Overview
Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Greenwich LifeSciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$12.34 |
| 52 Week High | US$21.44 |
| 52 Week Low | US$7.58 |
| Beta | 3.19 |
| 1 Month Change | -39.27% |
| 3 Month Change | 41.51% |
| 1 Year Change | 19.23% |
| 3 Year Change | -67.67% |
| 5 Year Change | n/a |
| Change since IPO | 146.80% |
Recent News & Updates
Recent updates
Here's Why We're Not Too Worried About Greenwich LifeSciences' (NASDAQ:GLSI) Cash Burn Situation
Jan 12
We're Not Very Worried About Greenwich LifeSciences' (NASDAQ:GLSI) Cash Burn Rate
Jan 29Greenwich LifeSciences: Persevering CEO And Interesting Data
Sep 06Greenwich LifeSciences halts stock buyback program
Jul 11Greenwich LifeSciences: A First Look
May 19Greenwich LifeSciences: Insider Buying And Buybacks Telegraph This Company's Vast Potential
Apr 21Companies Like Greenwich LifeSciences (NASDAQ:GLSI) Are In A Position To Invest In Growth
Feb 01We Think Greenwich LifeSciences (NASDAQ:GLSI) Can Afford To Drive Business Growth
Sep 30We're Not Very Worried About Greenwich LifeSciences' (NASDAQ:GLSI) Cash Burn Rate
Apr 04Are Insiders Buying Greenwich LifeSciences, Inc. (NASDAQ:GLSI) Stock?
Feb 16
What Is The Ownership Structure Like For Greenwich LifeSciences, Inc. (NASDAQ:GLSI)?
Dec 25Greenwich LifeSciences: Optimism On 'GP2' Breast Cancer Immunotherapy Candidate
Dec 23Greenwich LifeSciences under stress on pricing upsized $26.4M equity offering
Dec 18Greenwich LifeSciences inks deal with Westport Bio for pre-clinical coronavirus vaccine candidates
Dec 15Greenwich LifeSciences trebles in value as breast cancer therapy shines in mid-stage trial
Dec 09Shareholder Returns
| GLSI | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -4.3% | 0.4% | 1.0% |
| 1Y | 19.2% | 0.9% | 21.9% |
Return vs Industry: GLSI exceeded the US Biotechs industry which returned 0.7% over the past year.
Return vs Market: GLSI underperformed the US Market which returned 24.9% over the past year.
Price Volatility
| GLSI volatility | |
|---|---|
| GLSI Average Weekly Movement | 14.7% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: GLSI's share price has been volatile over the past 3 months.
Volatility Over Time: GLSI's weekly volatility has increased from 9% to 15% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 5 | Snehal Patel | greenwichlifesciences.com |
Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018.
Greenwich LifeSciences, Inc. Fundamentals Summary
| GLSI fundamental statistics | |
|---|---|
| Market cap | US$158.92m |
| Earnings (TTM) | -US$8.89m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-17.9x
P/E RatioIs GLSI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GLSI income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$8.89m |
| Earnings | -US$8.89m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.69 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did GLSI perform over the long term?
See historical performance and comparison